Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: Consensus, controversy, and conundrum

Journal of Clinical Oncology

Volumn 24, Issue 17, 2006, Pages 2612-2617

  Brizel, David M ^a   Esclamado, Ramon ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; MITOMYCIN; ANTINEOPLASTIC AGENT; CETUXIMAB; MONOCLONAL ANTIBODY; TIRAPAZAMINE; TRIAZINE DERIVATIVE;

CANCER CHEMOTHERAPY; HEAD AND NECK CARCINOMA; HUMAN; MULTIPLE CYCLE TREATMENT; NECK DISSECTION; ORGAN PRESERVATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; SQUAMOUS CELL CARCINOMA; CANCER INVASION; CANCER STAGING; CLINICAL TRIAL; CONSENSUS; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; HEAD AND NECK TUMOR; MULTIMODALITY CANCER THERAPY; PATIENT SELECTION; PRACTICE GUIDELINE; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; CONSENSUS; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; HEAD AND NECK NEOPLASMS; HUMANS; NECK DISSECTION; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PATIENT SELECTION; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; TRIAZINES;

EID: 33748175037     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.2829     Document Type: Review

References (70)

1. Pignon JP, Bourhis J, Domenge C, et al: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data - MACH-NC Collaborative Group, Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355:949-955, 2000
2. Pignon JP, Baujat B, Bourhis J: Individual patient data meta-analyses in head and neck carcinoma: What have we learnt? Cancer Radiother 9:31-36, 2005
3. Forastiere AA, Goepfert H, Maor M, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091-2098, 2003
4. Taylor SG, Murthy AK, Vannetzel JM, et al: Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol 12:385-395, 1994
5. Forastiere AA, Ang K, Brizel D, et al: Head and neck cancers. J Natl Compr Canc Netw 3:316-391, 2005
6. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer: The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 324:1685-1690, 1991
7. Clevens RA, Esclamado RM, Hartshorn DO, et al: Voice rehabilitation after total laryngectomy and tracheoesophageal puncture using nonmuscle closure. Ann Otol Rhinol Laryngol 102:792-796, 1993
8. Scharpf J, Esclamado RM: Reconstruction with radial forearm flaps after ablative surgery for hypopharyngeal cancer. Head Neck 25:261-266, 2003
9. Denis F, Garaud P, Bardet E, et al: Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 22:69-76, 2004
10. Maguire PD, Meyerson MB, Neal CR, et al: Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community. Int J Radiat Oncol Biol Phys 58:698-704, 2004
11. Denis F, Garaud P, Bardet E, et al: Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: Comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys 55:93-98, 2003
12. Adelstein DJ, Saxton JP, Rybicki LA, et al: Multi-agent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: Mature results from a single institution. J Clin Oncol 24:1064-1071, 2006
13. Barkley HT Jr, Fletcher GH, Jesse RH, et al: Management of cervical lymph node metastases in squamous cell carcinoma of the tonsillar fossa, base of tongue, supraglottic larynx, and hypopharynx. Am J Surg 124:462-467, 1972
14. Mendenhall WM, Villaret DB, Amdur RJ, et al: Planned neck dissection after definitive radiotherapy for squamous cell carcinoma of the head and neck. Head Neck 24:1012-1018, 2002
15. Brizel DM, Prosnitz RG, Hunter S, et al: Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 58:1418-1423, 2004
16. Clayman GL, Johnson CJ II, Morrison W, et al: The role of neck dissection after chemoradiotherapy for oropharyngeal cancer with advanced nodal disease. Arch Otolaryngol Head Neck Surg 127:135-139, 2001
17. Stenson KM, Haraf DJ, Pelzer H, et al: The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: The feasibility of selective neck dissection. Arch Otolaryngol Head Neck Surg 126:950-956, 2000
18. Robbins KT, Ferlito A, Suarez C, et al: Is there a role for selective neck dissection after chemoradiation for head and neck cancer? J Am Coll Surg 199:913-916, 2004
19. Grabenbauer GG, Rodel C, Ernst-Stecken A, et al: Neck dissection following radiochemotherapy of advanced head and neck cancer: For selected cases only? Radiother Oncol 66:57-63, 2003
20. Narayan K, Crane CH, Kleid S, et al: Planned neck dissection as an adjunct to the management of patients with advanced neck disease treated with definitive radiotherapy: For some or for all? Head Neck 21:606-613, 1999
21. McHam SA, Adelstein DJ, Rybicki LA, et al: Who merits a neck dissection after definitive chemoradiotherapy for N2-N3 squamous cell head and neck cancer? Head Neck 25:791-798, 2003
22. Yao M, Smith RB, Graham MM, et al: The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys 63:991-999, 2005
23. Farber LA, Benard F, Machtay M, et al: Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-2-deoxy- D-glucose positron emission tomography. Laryngoscope 109:970-975, 1999
24. Hicks RJ, Rischin D, Fisher R, et al: Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging 32:1384-1391, 2005
25. Eschmann SM, Paulsen F, Reimold M, et al: Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 46:253-260, 2005
26. Kubota K, Yokoyama J, Yamaguchi K, et al: FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: Comparison with MRI/CT. Eur J Nucl Med Mol Imaging 31:590-595, 2004
27. Lonneux M, Lawson G, Ide C, et al: Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope 110:1493-1497, 2000
28. Vermorken JB, Remenar E, van Herpen C, et al: Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): A phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971). J Clin Oncol 22:490s, 2004 (suppl; abstr 5508)
29. Brizel DM, Wasserman TH, Henke M, et al: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18:3339-3345, 2000
30. Wendt TG, Grabenbauer GG, Rodel CM, et al: Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. J Clin Oncol 16:1318-1324, 1998
31. Bernier J: Alteration of radiotherapy fractionation and concurrent chemotherapy: A new frontier in head and neck oncology? Nat Clin Pract Oncol 2:305-314, 2005
32. Brizel DM, Albers ME, Fisher SR, et al: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338:1798-1804, 1998
33. Huguenin P, Beer KT, Allal A, et al: Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 22:4665-4673, 2004
34. Jeremic B, Shibamoto Y, Milicic B, et al: Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial. J Clin Oncol 18:1458-1464, 2000
35. Al-Sarraf M, LeBlanc M, Giri PG, et al: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol 16:1310-1317, 1998
36. Adelstein DJ, Li Y, Adams GL, et al: An Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92-98, 2003
37. Bensadoun RJ, Dassonville O, Ramaioli A, et al: Phase III multicenter randomized study of concurrent twice-a-day radiotherapy with and without cisplatin-5FU (BiRCF) in unresectable pharyngeal carcinoma: Results at 18 months (FNCLCC-GORTEC). J Clin Oncol 22:489s, 2004 (suppl; abstr 5504)
38. Kurihara N, Kubota T, Hoshiya Y, et al: Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions. J Surg Oncol 62:135-138, 1996
39. Nagai N, Ogata H: Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: Importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo. Cancer Chemother Pharmacol 40:11-18, 1997
40. Morris M, Eifel PJ, Lu J, et al: Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340:1137-1143, 1999
41. Rose PG, Bundy BN, Watkins EB, et al: Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340:1144-1153, 1999
42. Thomas GM: Improved treatment for cervical cancer-concurrent chemotherapy and radiotherapy. N Engl J Med 340:1198-1200, 1999
43. Peters WA III, Liu PY, Barrett RJ II, et al: Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18:1606-1613, 2000
44. Bernier J, Domenge C, Ozsahin M, et al: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945-1952, 2004
45. Cooper JS, Pajak TF, Forastiere AA, et al: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937-1944, 2004
46. Moeller BJ, Cao Y, Li CY, et al: Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation, free radicals, and stress granules. Cancer Cell 5:429-441, 2004
47. Koukourakis MI, Giatromanolaki A, Sivridis E, et al: Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 53:1192-1202, 2002
48. Graeber TG, Osmanian C, Jacks T, et al: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379:88-91, 1996
49. Hockel M, Schlenger K, Aral B, et al: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56:4509-4515, 1996
50. Koukourakis MI, Giatromanolaki A, Sivridis E, et al: Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 7:3399-3403, 2001
51. Brizel DM, Dodge RK, Clough RW, et al: Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother Oncol 53:113-117, 1999
52. Fyles AW, Milosevic M, Wong R, et al: Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 48:149-156, 1998
53. Becker A, Hansgen G, Bloching M, et al: Oxygenation of squamous cell carcinoma of the head and neck: Comparison of primary tumors, neck node metastases, and normal tissue. Int J Radiat Oncol Biol Phys 42:35-41, 1998
54. Brizel DM, Sibley GS, Prosnitz LR, et al: Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38:285-289, 1997
55. Brizel DM, Scully SP, Harrelson JM, et al: Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56:941-943, 1996
56. Nordsmark M, Bentzen SM, Rudat V, et al: Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy: An international multi-center study. Radiother Oncol 77:18-24, 2005
57. Gatzemeier U, Rodriguez G, Treat J, et al: Tirapazamine-cisplatin: The synergy. Br J Cancer 77:15-17, 1998 (suppl 4)
58. Koch CJ: Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res 53:3992-3997, 1993
59. Tuttle SW, Hazard L, Koch CJ, et al: Bioreductive metabolism of SR-4233 (WIN 59075) by whole cell suspensions under aerobic and hypoxic conditions: Role of the pentose cycle and implications for the mechanism of cytotoxicity observed in air. Int J Radiat Oncol Biol Phys 29:357-362, 1994
60. Rischin D, Peters L, Fisher R, et al: Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23:79-87, 2005
61. Rischin D, Peters L, Hicks R, et al: Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 19:535-542, 2001
62. Ang KK, Berkey BA, Tu X, et al: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62:7350-7356, 2002
63. Kyzas PA, Cunha IW, Ioannidis JP: Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: A meta-analysis. Clin Cancer Res 11:1434-1440, 2005
64. Vokes EE, Cohen EEW, Mauer AM, et al: A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). J Clin Oncol 23:501s, 2005 (suppl; abstr 5504)
65. Horiot JC, Le Fur R, N'Guyen T, et al: Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 25:231-241, 1992
66. Fu KK, Pajak TF, Trotti A, et al: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 48:7-16, 2000
67. Overgaard J, Hansen HS, Specht L, et al: Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362:933-940, 2003
68. Budach VG, Stuschke M, Haake K, et al: Accelerated chemoradiation to 70.6 Gy is more effective than accelerated radiation to 77.6 Gy alone: Two year results of a German multicenter randomized trial. Int J Radiat Oncol Biol Phys 48:150, 2000 (suppl)
69. Budach V, Stuschke M, Budach W, et al: Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: Final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 prospective randomized trial. J Clin Oncol 23:1125-1135, 2005
70. Herbst RS, Arquette M, Shin DM, et al: Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23:5578-5587, 2005